bims-necame 2025-08-17 papers

Cell Rep. 2025 08 09. pii: S2211-1247(25)00925-8. [Epub ahead of print]44(8): 116154

Retraction Notice to: ASCL1 is activated downstream of the ROR2/CREB signaling pathway to support lineage plasticity in prostate cancer.

Nakisa Tabrizian, Shaghayegh Nouruzi, Cassandra Jingjing Cui, Maxim Kobelev, Takeshi Namekawa, Ishana Lodhia, Amina Talal, Olena Sivak, Dwaipayan Ganguli, Amina Zoubeidi.

DOI: https://doi.org/10.1016/j.celrep.2025.116154

bioRxiv. 2025 Jul 19. pii: 2025.07.18.664790. [Epub ahead of print]

SOX2 utilizes FOXA1 as a heteromeric transcriptional partner to drive proliferation in therapy-resistant prostate cancer.

Treatment options and diagnostic outlook for men with advanced, therapy resistant prostate cancer (PCa) are extremely poor; this is primarily due to the common lack of durable response to androgen receptor (AR) targeted therapies and phenotypic transdifferentiation into a particularly lethal subtype known as neuroendocrine prostate cancer (NEPC). In this study, we mechanistically determine that SOX2 (a transcription factor originally repressed by AR) physically binds and acts in a concerted manner with FOXA1 (a key AR pioneering cofactor) to regulate a subset of genes which promote cell cycle progression, and lineage plasticity in AR-refractory prostate cancers. Our findings assert the SOX2/FOXA1 interaction as an important mediator of resistance to AR-targeted therapy and a driver of NEPC and lineage plasticity; their coordinated action and downstream signaling offers a potential novel therapeutic opportunity in late-stage PCa.

DOI: https://doi.org/10.1101/2025.07.18.664790

Clin Nucl Med. 2025 Aug 14.

PSMA-negative Widespread Metastases Identified by 18F-FDG PET/CT in Treatment-related Neuroendocrine Prostate Cancer With Squamous Differentiation.

Yujia Li, Xiaomei Gao, Jinhui Yang, Yongxiang Tang, Shuo Hu.

A 62-year-old man had prostate cancer treated for 5 years with prostatectomy, radiation, and hormonal therapy. He presented with worsening back pain for 3 months. Serum prostate-specific antigen was very low (<1.0 ng/mL), while neuron-specific enolase was elevated (23.35 ng/mL), raising suspicion of neuroendocrine differentiation. Dual-tracer PET/CT was performed. 68Ga-PSMA PET/CT showed no recurrence or metastasis, while 18F-FDG PET/CT revealed widespread hypermetabolic bone lesions and retrocrural nodal disease. Biopsy confirmed treatment-related neuroendocrine prostate cancer with squamous differentiation. This rare phenotype exhibited typical PSMA-negativity and intense FDG uptake. It emphasizes the diagnostic potential of 18F-FDG PET/CT in dedifferentiated prostate cancers.

Keywords: FDG; PET/CT; PSMA-negative; neuroendocrine prostate cancer; squamous differentiation

DOI: https://doi.org/10.1097/RLU.0000000000006106

BMC Med Imaging. 2025 Aug 14. 25(1): 330

The baseline 18F-FDG PET/CT imaging features in pediatric patients with congenital neuroblastoma.

Keyu Zhang, Guanyun Wang, Xiaoya Wang, Ying Kan, Wei Wang, Jigang Yang.

PURPOSE: Congenital neuroblastoma represents a distinct subtype of neuroblastoma that originates during fetal and neonatal development. Limited research has been conducted on the prognostic significance of baseline Fluorine-18-Fluorodeoxyglucose positron emission tomography/computerized tomography (18F-FDG PET/CT) in pediatric patients with congenital neuroblastoma. This study aims to characterize the baseline 18F-FDG PET/CT imaging features in children with congenital neuroblastoma.
METHODS: A retrospective collection was performed using imaging and clinical data from pediatric patients diagnosed with congenital neuroblastoma who underwent 18F-FDG PET/CT at the Beijing Friendship Hospital, Capital Medical University between June 2020 and June 2023. We collected clinical and 18F-FDG PET metabolic parameters, including maximum standardized uptake value, mean standardized uptake value (SUVmean), metabolic tumor volume (MTV), and total lesion glycolysis (TLG), total-body MTV and total-body TLG. Patients were categorized into the recurrence group and the non-recurrence group based on the follow-up outcomes.
RESULTS: A total of 28 pediatric patients with congenital neuroblastoma were included in the study. There are 26 patients exhibited elevated serum NSE levels, 25 patients exhibited elevated serum LDH levels. Only 3 patients had MYCN amplification. 5 patients had 11q23 aberration. Primary tumors were located in the abdomen or mediastinum in all but two patients, who had pelvic and cervical involvement. All primary tumor had high FDG uptake. 6 patients had liver metastases, and 1 patient showed normal FDG uptake. 4 patients had bone marrow metastases, all of them showed high FDG uptake. With a median follow-up of 711 days, 23 patients had progression free survival, and 5 cases of recurrence.
CONCLUSION: Our study showed that the prognosis of congenital neuroblastoma was generally favorable and 18F-FDG PET/CT is valuable for the diagnosis and staging in congenital neuroblastoma.

Keywords: 18F-FDG PET/CT; Congenital neuroblastoma; Metabolic parameters; Prognosis

DOI: https://doi.org/10.1186/s12880-025-01863-2